Literature DB >> 35286546

Leveraging the Prescription Drug Monitoring Program to Curb Opioid Prescribing in Arkansas.

Corey J Hayes1,2, Johnathan Goree3, Jamie Turpin4, Haley Ortiz4, G Richard Smith4,5, Srinivasa B Gokarakonda4,5, Carrie Hyde6, Michael A Cucciare7,8,9.   

Abstract

Effective means of accurately identifying problematic opioid prescribing are needed. Using an iterative approach with the Arkansas State Medical Board Pain Subcommittee, we modified existing opioid prescriber criteria to create seven metrics to be deployed in Arkansas. These included metrics of dose and days' supply, concomitant use of opioid and benzodiazepines, solid dosage units, and numbers of opioid patients and certain opioid prescriptions. Two of these metrics (average MME daily dose per prescription and total oxycodone 30 mg or hydromorphone prescriptions) were weighted by 2, creating a maximum score of 9 of which each prescriber could receive. Twenty prescribers with a score of 7 or greater were identified and referred to the Arkansas State Medical Board Pain Subcommittee for review and subsequent investigation if deemed necessary. Of those 20 prescribers, four were previously investigated and under disciplinary action, and three were under current investigation for misconduct related to prescribing practices. Five prescribers had new investigations opened due to the findings from the metrics, and disciplinary action was taken. Therefore, 12 of the 20 prescribers referred to the Arkansas State Medical Board were deemed worthy of investigation and disciplinary action. The Arkansas opioid prescriber metrics are able to accurately identify prescribers with potentially problematic opioid prescribing.
© 2022. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.

Entities:  

Keywords:  Opioid prescribing; Opioids; Pain; Policy

Mesh:

Substances:

Year:  2022        PMID: 35286546      PMCID: PMC9117447          DOI: 10.1007/s10935-022-00670-7

Source DB:  PubMed          Journal:  J Prev (2022)        ISSN: 2731-5533


  34 in total

1.  A comparison of performance assessment programs for medical practitioners in Canada, Australia, New Zealand, and the United kingdom.

Authors:  Paul M Finucane; Gisèle A Bourgeois-Law; Sue L Ineson; Tiina M Kaigas
Journal:  Acad Med       Date:  2003-08       Impact factor: 6.893

2.  How does use of a prescription monitoring program change medical practice?

Authors:  Traci C Green; Marita R Mann; Sarah E Bowman; Nickolas Zaller; Xaviel Soto; John Gadea; Catherine Cordy; Patrick Kelly; Peter D Friedmann
Journal:  Pain Med       Date:  2012-07-30       Impact factor: 3.750

3.  Reductions in prescription opioid diversion following recent legislative interventions in Florida.

Authors:  Hilary L Surratt; Catherine O'Grady; Steven P Kurtz; Yamilka Stivers; Theodore J Cicero; Richard C Dart; Minxing Chen
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-03       Impact factor: 2.890

Review 4.  Relationship between Nonmedical Prescription-Opioid Use and Heroin Use.

Authors:  Wilson M Compton; Christopher M Jones; Grant T Baldwin
Journal:  N Engl J Med       Date:  2016-01-14       Impact factor: 91.245

5.  Geographic variation in the prescription of schedule II opioid analgesics among outpatients in the United States.

Authors:  Lesley H Curtis; Jennifer Stoddard; Jasmina I Radeva; Steve Hutchison; Peter E Dans; Alan Wright; Raymond L Woosley; Kevin A Schulman
Journal:  Health Serv Res       Date:  2006-06       Impact factor: 3.402

6.  Relationship between high-risk patients receiving prescription opioids and high-volume opioid prescribers.

Authors:  Hsien-Yen Chang; Irene B Murimi; Christopher M Jones; G Caleb Alexander
Journal:  Addiction       Date:  2017-11-29       Impact factor: 6.526

Review 7.  Patient Outcomes in Dose Reduction or Discontinuation of Long-Term Opioid Therapy: A Systematic Review.

Authors:  Joseph W Frank; Travis I Lovejoy; William C Becker; Benjamin J Morasco; Christopher J Koenig; Lilian Hoffecker; Hannah R Dischinger; Steven K Dobscha; Erin E Krebs
Journal:  Ann Intern Med       Date:  2017-07-11       Impact factor: 25.391

8.  Crowdsourcing black market prices for prescription opioids.

Authors:  Nabarun Dasgupta; Clark Freifeld; John S Brownstein; Christopher Mark Menone; Hilary L Surratt; Luke Poppish; Jody L Green; Eric J Lavonas; Richard C Dart
Journal:  J Med Internet Res       Date:  2013-08-16       Impact factor: 5.428

9.  Vital Signs: Changes in Opioid Prescribing in the United States, 2006-2015.

Authors:  Gery P Guy; Kun Zhang; Michele K Bohm; Jan Losby; Brian Lewis; Randall Young; Louise B Murphy; Deborah Dowell
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-07-07       Impact factor: 17.586

10.  Vital Signs: Trends in Emergency Department Visits for Suspected Opioid Overdoses - United States, July 2016-September 2017.

Authors:  Alana M Vivolo-Kantor; Puja Seth; R Matthew Gladden; Christine L Mattson; Grant T Baldwin; Aaron Kite-Powell; Michael A Coletta
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-03-09       Impact factor: 17.586

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.